Epilepsy, a chronic neurological disorder, is characterized by recurrent seizures affecting people of all ages. Despite the availability of numerous anti-epileptic drugs (AEDs), a significant proportion of patients continue to experience uncontrolled seizures. This necessitates a continuous pursuit of advancements in the management of epilepsy.
Recent years have witnessed the introduction of new generation AEDs with unique mechanisms of action. These include Brivaracetam, Perampanel, and Lacosamide, which have shown promising results in terms of efficacy and tolerability. These drugs target novel pathways, thus expanding treatment options for refractory epilepsy.
Neuromodulation techniques such as Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), and Responsive Neurostimulation (RNS) have emerged as effective treatment strategies. These interventions modulate neuronal activity, reducing seizure frequency and severity. While invasive, their use is justified in drug-resistant cases.
With the advent of next-generation sequencing, genetic testing has become increasingly relevant in epilepsy management. Identification of specific genetic mutations can guide the choice of AEDs, paving the way for precision medicine in epilepsy.
The COVID-19 pandemic has accelerated the adoption of telemedicine in epilepsy care. Virtual consultations, remote monitoring of seizure activity, and online delivery of cognitive behavioral therapy have proven effective and convenient for patients, particularly those residing in remote areas.
Advancements in epilepsy management, from novel AEDs to neuromodulation techniques, genetic testing, and telemedicine, have significantly improved patient outcomes. As we continue to explore these frontiers, it is crucial for healthcare professionals to stay updated and adapt to these changes, ensuring optimal care for patients with epilepsy.
1.
Tumor characteristics found to differ for melanomas in children, teens and young adults
2.
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials
3.
"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.
4.
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies
5.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
1.
Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care
2.
Screening for Early Therapy-Related Cancer Susceptibility
3.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
4.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
5.
Reducing Modifiable Childhood Cancer Exposure Risks
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
3.
Should We Use DARA Up Front As First-Line Therapy in MM?
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
Importance of Cancer Screening and Early Detection
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation